Evaluation of Event Time of Neuropathy in Type 2 Diabetic Patients: Application of Surrogate Endpoints Method

Jamileh Abolghasemi¹, Mina Motamedi Rad¹*, Fahimeh Soheilipour², Hamid Reza Baradaran³, Shahnaz Rimaz², Sadegh Kargarian Marvasti⁴

¹. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
². Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran
³. Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
⁴. Fereydunshahr Health Center, Isfahan University of Medical Sciences, Isfahan, Iran

* Correspondence to: Mina Motamedi Rad, Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. E-mail: mina.motamedi@outlook.com

Abstract

Background: Diabetic neuropathy is the most common complication of diabetes, the effective control of which requires accurate diagnosis of neuropathy on a regular basis. The present study aimed to investigate the factors affecting the event time of neuropathy using the Clayton copula model in type 2 diabetic patients in the presence of a surrogate response variable.

Methods: The data of all the people whose diabetes test results were negative in the 2006 screening by the health centers in Ferey dun Shahr, Isfahan, but their diabetes re-tests were positive in 2007, and were at least 30 years of age were collected, and their neuropathy status was followed up for at least 10 years. To investigate the factors affecting the event time of neuropathy in the patients, the Clayton copula model as well as the true variable, ten-point monofilament test and surrogate variable, and Michigan questionnaire including interviews and examinations by a trained physician were used. All the statistical analyzes were performed using the R software (version 3.6.2) and tests were done with an error of 0.05.

Results: Of the total of 371 diabetic patients studied, 114 (30.7%) were male and their mean age was 63.93 (±0.568) years. According to the Clayton copula model, the individuals with a family history of diabetes and Hemoglobin A1c of >=8.1, BMI of >=35, HDL of <54, and under treatment with oral and insulin injections would develop neuropathy more quickly.

Conclusion: In this study, using the survival ROC curve, was shown that the Copula model was more efficient than the surrogate model, so it is suggested that the Copula model be used to predict the occurrence of neuropathy for patients who do not have access to the monofilament test.
1. Background
Peripheral neuropathy and vascular diseases are major causes of diabetic foot. The problems associated with diabetic foot are responsible for many cases of hospitalization of such patients, and foot ulcer and amputation are common complications of diabetes. Neuropathy pain can be severe and may limit mobility and cause depression as well as disruption of the patient's social activities (1). All the patients are needed to be examined for peripheral neuropathy after diagnosis of type 2 diabetes (2). In a prospective study, about 10% of the diabetic patients had neuropathy at the time of diagnosis (3). Diabetic neuropathy is one of the most common complications of diabetes (4), occurring in 40-50% of the patients who have been diagnosed with diabetes for at least 25 years (5). Motor and sensory neuropathy often occurs in the legs and is chronic and progressive, with pain in the extremities. The legs gradually become numb and prone to ulcers, burns, infections, gangrene, and Charcot joints (6). Early detection and control of diabetes and its risk factors (7) can help prevent or delay the progression of diabetic neuropathy (8). Early diagnosis of neuropathy is also of particular importance and can prevent more severe complications and huge economic costs. The use of a simple and inexpensive method in clinics to screen for peripheral neuropathy will be of great value. Using the Michigan Questionnaire and the Monofilament Test is a simple, inexpensive, and clinically applicable method for screening for peripheral neuropathy in diabetic patients. All the patients with type 2 diabetes should be examined annually on the basis of their medical history and simple clinical tests for peripheral diabetic neuropathy after diabetes diagnosis (9).

In this study, the time of neuropathy diagnosis through probabilistic and rapid diagnosis in clinical conditions (Michigan questionnaire including interviews and examinations by a trained physician) and the time of neuropathy diagnosis through definitive diagnosis with the monofilament test were considered as surrogate and true endpoints, respectively. The aim of this study was to evaluate the event time of neuropathy in type 2 diabetic patients, using surrogate endpoint methods.

2. Methods
To collect the data, all the people whose diabetes test results were negative in the 2006 screening by the health centers in Fereidounshahr, Isfahan, underwent diabetes
re-tests in 2007, and those with positive test results were enrolled in the study in case they were ≥30 years of age, and their neuropathy status was followed up for at least 10 years. In this study, the response variable was the time of diabetes diagnosis until the time of neuropathy diagnosis. Thus, the Michigan questionnaire was first used to take the patients' medical history, and they were asked about the symptoms of neuropathy. Their skin and nails conditions were also checked. In the Michigan Questionnaire, the four factors including the appearance of foot skin (in terms of dryness or cracks, calluses, infection, and deformity), ulcers, Achilles tendon, and vibration sense measured with a 128 Hz tuning fork in the big toe are assessed, and the scores higher than 2 indicate the incidence of neuropathy (10). This method was used to diagnose neuropathy in all the patients studied in the present research. To detect neuropathy, the 10g monofilament and 128 Hz tuning fork are used, and the ten-point monofilament test is performed on ten points on the sole and dorsum of the foot. The lack of monofilament at one or more points indicates peripheral neuropathy (11). The test is performed on a small number of patients and is not available to all patients.

The failure time was by month and based on the censored cases included those who were not diagnosed with neuropathy at the end of the study, those who died, and the ones missed in the follow-up (immigrants) before the end of the study. Reviewing the patients' medical records and, if necessary, doing in-person interviews and telephone calls, the researchers obtained the information on variables such as demographic variables (gender, age, occupation, education, place of residence, region of residence, Race, diabetes in first-degree relatives, diabetes treatment methods, smoking), laboratory variables (FBS, height, weight, BMI, cholesterol, triglyceride, HDL, LDL, Creatinine, HbA1c, diastolic and systolic blood pressures, and clinical diagnostic and questionnaire variables of neuropathy).

In statistical modeling, the researcher seeks to estimate the response variable. If measuring the response variable is difficult in terms of cost, difficulty, and such factors, it should be replaced with a surrogate variable that can be measured with a lower cost or in a shorter time to diagnose the disease or can be measurable for more people through generalized methods. Modeling in surrogate endpoint methods is performed with regard to the type of the true and surrogate endpoints (12).

When both endpoints are of the failure time type, the co-survival model can be applied, in which a bivariate distribution function with a copula function of any distribution type can be used for the survival function or the marginal risk of the two endpoints (12). The co-survival model (the one with surrogate endpoints) is a model in which both true and surrogate endpoints are of the failure time and correlated. The model is defined as follows:
\[ F(s, t) = P(S_{ij} \geq s, T_{ij} \geq t) = C_{\theta}\{F_{S_{ij}}(s), F_{T_{ij}}(t)\}, s, t \geq 0. \] (2.1)

Where \( F_{S_{ij}} \) and \( F_{T_{ij}} \) are marginal survival functions, and \( C_{\theta} \) is the copula function, i.e. bivariate distribution functions are defined in \([-1, 1]^2\). In this model, any copula function can be used.

When the risk functions are known, the estimation of the paired model parameters will be through maximum likelihood estimation. In this model, various copulas can be used, depending on the probable intrinsic relationship between the surrogate and true endpoints. General assumptions for fitting the best copula model are not available, and the relation parameter can be difficult to interpret, but the following relation can be obtained by Kendall tau:

\[
\tau = 4 \int_{0}^{1} \int_{0}^{1} C_{\theta}(s, t) C_{\theta}(ds, dt)
\] (2.2)

This coefficient indicates the relationship between the surrogate and true endpoints (12, 13).

The Kendall's \( \tau \) in the Clayton copula model (14) is as follows:

\[
\tau_{kendall} = \theta - 1/\theta + 1
\] (2.3)

The survival function of the Clayton copula model is as follows:

\[
S(t_1, t_2; \beta, \theta) = [S_1(t_1, \beta)^{1-\theta} + S_2(t_2, \beta)^{1-\theta} - 1]^\frac{1}{\theta-1}
\] (2.4)

Where \( S_1 (t_1; \beta) \) and \( S_2 (t_2; \beta) \) are the marginal survival functions for each pair of neuropathy diagnosis times \((T_1, T_2)\), \( \theta > 1 \) is the parameter measuring the positive relationship between survival times, and \( \beta \) is a vector of marginal parameters. If the pairs are ranked, the \( \beta \) vector will be the model parameters. Otherwise, marginal distributions will be completely equal. If \( \theta = 1 \), the survival times will be independent (15). The Weibull marginal survival distribution is as follows:

\[
S(t) = \exp\left\{ -\left(\frac{t}{\lambda}\right)^k e^{\theta^2 \beta} \right\}
\] (2.5)

Where \( \lambda > 0 \) is the scale parameter, \( k > 0 \) is the shape parameter, and \( \beta \) shows the parameters related to the variables. According to this model, the variables effects are proportional in the context of the risks (13).
To perform the modeling, each model was fitted with an auxiliary variable using the simple regression, and the variables with a P value of <0.2 were nominated to enter the multiple model. Using progressive and regressive methods, the Clayton copula multiple model was fitted with Weibull distribution, and the efficiency of the fitted model was then determined using survival curves.

The survival-related ROC curve is a method for evaluating the efficiency of fitted survival models. The curve graphically shows correct prediction or sensitivity versus false prediction by time. It can also be plotted to examine the survival prediction trends in 3-month, 6-month, 24-month, and 36-month sections (16-18). The AUC was used in this study to compare the accuracy of the models. The closer the AUC value to 1 or the larger the area under the curve, the higher the accuracy of the model would be. The Weibull Clayton copula survival model and the surrogate Weibull survival model were used for survival analysis in the present research.

3. Results

![Kaplan-Meier survival estimates](image)

Figure 1: Estimation of survival time in neuropathic event with monofilament ten-point test (true endpoint), Michigan questionnaire including interview and examination by a trained physician (surrogate endpoint), and both Michigan questionnaire and monofilament ten-point test (Copula)

Figure 1 indicates that estimate of survival time in neuropathic event with monofilament ten-point test (true endpoint), was higher than Michigan questionnaire because in this study the monofilament test was performed for patients later. The Michigan questionnaire including interviews and examinations by a trained physician were used for all the 371 diabetic patients (100%), and 244 patients
(65.8%) underwent the ten-point monofilament test for neuropathy diagnosis. Table (1) shows the comparison of demographic information and laboratory results of the studied patients by the type of neuropathy diagnosis. The table also represents the frequency of the individuals for each diagnosis method.

In the survival analysis with an auxiliary variable (single regression) using the Clayton copula model with Weibull distribution, the variables including gender, family history, type of treatment, occupational activity, BMI, HbA1c, HDL, BUN and Race were significant at 0.2 level.

Table 1: Comparison of descriptive of demographic and laboratory variables

| variables          | Diagnosis by Michigan questionnaire Frequency (%) | Diagnosis by Monofilament test Frequency (%) | Statistic $X^2$ | P     |
|--------------------|---------------------------------------------------|---------------------------------------------|----------------|-------|
| Gender             |                                                   |                                             |                |       |
| Male               | 41 (32.3%)                                        | 73 (29.9%)                                  | 0.220          | 0.639 |
| Female             | 86 (67.7%)                                        | 171 (70.1%)                                 |                |       |
| Race               |                                                   |                                             |                |       |
| Georgia            | 47 (37%)                                          | 90 (36.9%)                                  | 0.153          | 0.985 |
| Bakhtiari          | 41 (32.3%)                                        | 76 (31.1%)                                  |                |       |
| Persia             | 12 (9.4%)                                         | 26 (10.7%)                                  |                |       |
| Tork               | 27 (21.3%)                                        | 52 (21.3%)                                  |                |       |
| Job activity       |                                                   |                                             |                |       |
| low                | 20 (15.7%)                                        | 37 (15.2%)                                  | 0.155          | 0.925 |
| moderate           | 85 (66.9%)                                        | 168 (68.9%)                                 |                |       |
| high               | 22 (17.3%)                                        | 39 (16.0%)                                  |                |       |
| Family History     |                                                   |                                             |                |       |
| Yes                | 45 (35.4%)                                        | 133 (54.5%)                                 | 12.177         | <0.001|
| No                 | 82 (64.6%)                                        | 111 (45.5%)                                 |                |       |
| Treatment          |                                                   |                                             |                |       |
| Oral               | 113 (89%)                                         | 194 (79.5%)                                 | 9.957          | 0.019 |
| Insulin injections | 6 (4.7%)                                          | 22 (9.0%)                                   |                |       |
| Both               | 4 (3.1%)                                          | 25 (10.3%)                                  |                |       |
| No.med             | 4 (3.1%)                                          | 3 (1.2%)                                    |                |       |
| Mean (±s.e)        | Mean (±s.e)                                       | statistic t                                | P              |
| Age                | 62.23±1.018                                       | 64.82±0.676                                 | -2.173         | 0.030 |
| FBS                | 166.11 (±6.302)                                   | 168.81 (±4.380)                             | -0.356         | 0.722 |
| BMI                | 28.53 (±0.312)                                    | 28.52 (±0.296)                              | 0.002          | 0.998 |
| HbA1c              | 8.13 (±0.211)                                     | 8.10 (±0.132)                               | 0.115          | 0.909 |
| Cholesterol        | 189.59 (±3.797)                                   | 200.00 (±3.272)                             | -1.962         | 0.050 |
| triglyceride       | 186.15 (±8.188)                                   | 191.57 (±7.705)                             | -0.444         | 0.657 |
| HDL                | 47.89 (±1.345)                                    | 47.70 (±1.178)                              | 0.102          | 0.919 |
| LDL                | 105.62 (±3.469)                                   | 109.86 (±2.505)                             | -0.990         | 0.323 |
| BUN                | 15.02 (±0.346)                                    | 16.93 (±0.476)                              | -2.706         | 0.007 |
| Creatinine         | 0.81 (±0.191)                                     | 0.84 (±0.192)                               | -1.099         | 0.272 |

s.e: standard error
In the final Clayton copula model, the relationship between the time of neuropathy diagnosis using the Michigan Questionnaire (surrogate endpoint) and the time of neuropathy diagnosis using the monofilament test (true endpoint) was about 89%, which was acceptable for nomination of the intended endpoint for replacing the true endpoint (13). In this model, the time of neuropathy diagnosis through the use of the Michigan questionnaire along with the monofilament test was considered as the paired survival time. According to this model that, people with a family history of diabetes and a body mass index of >=35 who were under treatment with both oral and insulin injections and their Hemoglobin A1c was higher than 8.1 would develop neuropathy sooner, but those with an HDL of >=54 would develop it later. These results are given in Table (2).

Table 2: Results of multiple analysis of weibull Clayton Copula

| Covariate               | estimate | SE     | stat  | P       |
|-------------------------|----------|--------|-------|---------|
| Scale                   |          |        |       |         |
| λ                       | 977.758  | 214.8661 | 20.707 | <0.001  |
| Shape                   |          |        |       |         |
| K                       | 0.686    | 0.0424 | 260.986 | <0.001  |
| Family.History          |          |        |       |         |
| No (base)               |          |        |       |         |
| +                       | 0.748    | 0.1477 | 25.670 | <0.001  |
| Treatment               |          |        |       |         |
| Oral (base)             |          |        |       |         |
| Oral & Insulin injections | 0.973   | 0.1647 | 34.882 | <0.001  |
| BMI                     |          |        |       |         |
| <35 (base)              |          |        |       |         |
| >=35                    | 0.717    | 0.2440 | 8.645 | 0.003   |
| HbA1c                   |          |        |       |         |
| <8.1 (base)             |          |        |       |         |
| >=8.1                   | 0.471    | 0.1483 | 10.088 | 0.001   |
| HDL                     |          |        |       |         |
| <54 (base)              |          |        |       |         |
| >=54                    | -0.496   | 0.2013 | 6.069 | 0.013   |
| θ (Relationship parameter) | 17.287  | 2.4396 | 50.212 | <0.001  |
| AIC                     |          |        |       |         |
|                         | 2108.812 |        |       |         |

AIC: Akaike Information Criterion

The results of comparing the survival from the Clayton copula modeling with Weibull distribution in which neuropathy in diabetic patients was assessed using the Michigan Questionnaire for all the patients, and the Clayton copula model in which neuropathy diagnosis was assessed using the Michigan questionnaire for all the patients and the monofilament test for a smaller number is shown in Figure 2, where the AUC values for comparing the efficiency of the two Clayton copula models and
the surrogate model can be seen. The AUC values of the Clayton copula Weibull model were always higher than that of the surrogate model, so that the Wilcoxon test indicated a significant difference between these values (P < 0.001), showing the higher efficiency of the Clayton copula model in estimating survival. As observed in (Figure 2), the copula model was better than the surrogate one, indicating the accuracy of the diagnostic method using the monofilament test along with the Michigan questionnaire.

In order to investigate the survival prediction trend using the Clayton Copula model with Weibull distribution in 3-month, 24-month, and 36-month time periods, the ROC curve was plotted and the values of the area under the curve were 0.958, 0.897, and 0.835, respectively. Thus, the trend represented the predictive strength in the early months which was weaker in subsequent periods (Figure 3).

Figure 4 shows that copula model is more accurate than surrogate model in predicting the event time of neuropathy in patients with neuropathy.

**Figure 2:** Accuracy of the Copula diagnosis (blue line) using the covariates of Family.History, Treatment, BMI, HbA1c and HDL vs. Surrogate Diagnosis (red line). Line Plot the Estimates of Incident/Dynamic AUC(t) Versus Time Under the Assumption of Proportional Hazards.
Figure 3: Comparison of the Area Under ROC Curves (AUC) for Predicting the event time of neuropathy at 3(AUC = 0.958), 24(AUC = 0.897), 36(AUC = 0.835) Months for Copula Diagnosis.
**Figure 4:** Comparison of the Area Under the ROC Curves (AUC) for predicting the event time of neuropathy at 3, 6, 24 and 36 Months Between Copula Diagnosis (solid line) and Surrogate Diagnosis (dash line). AUC for Prediction of event time of neuropathy using the Copula at 3 (AUC=0.958), 6 (AUC=0.939), 24 (AUC=0.897), 36 (AUC=0.835) Month and AUC for Prediction event time of neuropathy using the Surrogate at 3 (AUC=0.926), 6 (AUC=0.915), 24 (AUC=0.856), 36 (AUC=0.790) Month.
4. Discussion

Diabetic neuropathy refers to a group of heterogeneous disorders with different clinical manifestations. Hence, rapid and timely diagnosis of neuropathy in patients with diabetes is of particular importance. Diagnosis of diabetic peripheral neuropathy is a unique process due to the presence of non-diabetic neuropathies which are often curable. There are numerous treatments for symptomatic non-diabetic neuropathies, but more than 50% of peripheral diabetic neuropathies may be asymptomatic. If the symptoms are not diagnosed and preventive feet care is not taken, the patient will be at risk of diabetic foot ulcer due to the numbness of the feet (2). In this study, neuropathy diagnosis was performed using the Michigan questionnaire including interviews and examinations by a trained physician for all patients (surrogate variable) and the ten-point monofilament test for a smaller number of patients (true variable). To compare the efficiency of the surrogate and the copula models, the AUC criterion was used as well. The AUC value for the model that used the Clayton Copula model (Michigan questionnaire along with the ten-point monofilament test) was close to 1, indicating a higher accuracy of the model than the surrogate variable (Michigan questionnaire). Furthermore, the values of the area under curve (AUC) for the 3-, 24-, and 36-month sections were declining, indicating a better fit of the model in the time near present. The accuracy of the estimation decreased as the time increased, so that the AUC decreased from 0.958 in the 3-month section to 0.835.

According to the results, a family history of diabetes in first-degree relatives was one of the important risk factors for neuropathy in this study (P <0.001). The hazard ratio for the patients with a family history of diabetes was about 2 times more than that of the ones without a family history of the disease (HR = 2.11, P <0.001). Thus, it could be hypothesized that there were genetic effects in the acceleration of neuropathy (19, 20). Numerous studies such as the ones by Nicholson G, Trivedi JR, and Tavakkoly-Bazzaz J emphasized the role of genetics (VEGFF polymorphism gene) in neuropathy development (19-21).

It was observed in this study that the type of treatment had an effect on the patients with neuropathy. The ratio of the disease in the patients taking oral medication and insulin simultaneously was 15.4%, whole it was 84.6% in those who were only taking oral medication. The hazard ratio for neuropathy in the former group was 2.64 times higher than in the latter, the reason for which could be the severity of the disease in the former. Unlike our study, the studies by Booya et al. (22) and Abbott (23) showed no significant relationship between the type of diabetes treatment and developing neuropathy. This might be due to the difference between the types of the studies and the response variable (survival analysis versus logistic regression).

In the present study, about 18.9% of the subject had HDL >=54 and 81.1% had HDL < 54. The Chi-square test showed that there was a significant difference between higher and lower HDL than 54 and the incidence of neuropathy (P = 0.012). Other studies such as the ones by Tesfaye S et al. (7) and Maser RE et al. (24) also confirmed this relationship. high-density lipoproteins (HDL), also known as the
good cholesterol, is responsible for transporting excess cholesterol to the liver and removing it from the body, and the higher its level, the lower the risk of heart diseases will be. In this study, high HDL levels were associated with a reduced risk of neuropathy (HR = 0.61, P = 0.013). HbA1c is one of the most important factors in diabetes, indicating the quality of diabetes control within the last three months. It is also a major indicator of diabetes care, which reflects the quality of self-care in the last three months. Many studies found high HbA1c effective in the incidence of neuropathy (7, 22, 25, 26). During diabetes, the speed and ability of the body to use up and metabolize glucose decreases; therefore, blood sugar increases and this is called hyperglycemia. The prolonged increase in sugar means an increase in diabetes duration (27, 28). Macrovascular complications (atherosclerosis) begin with damage to the walls of the arteries, leading to chronic inflammation of the arteries, infiltration of immune cells, deposition of fat from LDL particles inside the arteries, and smooth muscle expansion (29). Microvascular complications of diabetes are caused by the destruction of very small blood vessels and can affect different parts of the body, such as the kidneys, eyes and nerves. Prolonged hyperglycemia will cause the destruction of peripheral nerve cells which are at greater risk because they are unable to regulate blood sugar absorption in the long term and can lead to neuropathy over several years. Hyperglycemia causes glucose to accumulate inside nerve cells. It is converted to sorbitol and fructose over time, which in turn leads to impaired axonal transmission, fragility of nerve membranes, and eventually, destruction of nerve cells. According to the Clayton copula model with Weibull distribution used in this study, the patients with a mean 3-month blood sugar of >=8.1 were about 1.60 times more likely to develop neuropathy (HR = 1.60, P <0.001). Several studies also found high HbA1c effective in the development of neuropathy (7, 22, 25, 26).

Neuropathy exposes the feet to ulcers by causing numbness and impaired proprioception in them. The reason is that the numbness and impaired proprioception of the feet cause them to be imposed excessive and inappropriate loads, and ulcers will appear in the areas that are exactly the points of pressure transfer, i.e. increased body mass index is associated with ulcer formation (30). In this study, BMI was another factor influencing the incidence of neuropathy. Foot care is also necessary for diabetic patients. Using appropriate medical tools and necessary training, they must avoid excessive pressure on their feet as much as possible. To this end, weight loss will also be effective. In the present study, the patients with a body mass index of >=35 were about twice as likely as those with lower BMIs to develop neuropathy (HR = 2.04, p = 0.003). This might be due to the greater pressure on their feet and also due to obesity. There is currently no specific treatment for nerve damage other than optimal blood sugar control that can effectively prevent peripheral neuropathy in diabetic patients (31, 32) and reduce the progression of peripheral neuropathy to a great extent (33). However, blood sugar control does not reverse the loss, and treatment strategies (pharmacological and non-pharmacological) to relieve the pain of diabetic peripheral neuropathy can potentially reduce pain (9) and improve the quality of life.
5. Conclusion

In this study, the Michigan questionnaire including interviews and examinations by a trained physician was used for all type 2 diabetic patients, and the ten-point monofilament test was performed on a limited number of them (65.8%) in order to diagnose neuropathy. Thus, the model which was fitted based on surrogate response variables (Michigan questionnaire) along with the true response variable (ten-point monofilament test) could efficiently estimate the event time of neuropathy.

People with a family history of diabetes, Hemoglobin A1c of $\geq 8.1$, BMI of $\geq 35$, HDL of $<54$, and under treatment with oral and insulin injections will develop neuropathy more quickly. Thus, it is recommended to provide more care and control to these patients once they are diagnosed with type 2 diabetes.

List of abbreviations

HbA1c (Hemoglobin A1c), BMI (Body Mass Index), HDL (High-Density Lipoprotein), LDL (Low-Density Lipoprotein), BUN (Blood Urea Nitrogen), FBS (Fasting Blood Sugar), BP sys (Blood Pressure systolic), BP dia (Blood Pressure diastolic), s.e (standard error), AIC (Akaike Information Criterion), ROC (Receiver Operating Characteristics), AUC (Area Under Curve), VEGGF (Vascular Endothelial Growth Gene Factor).

Declarations

- Ethics approval and consent to participate

To collect data, the information recorded in the electronic file stored in health centers with a written ethics license with the number IR.IUMS.REC.1398.322 from the Faculty of Health of Iran University of Medical Sciences was used and all methods were carried out in accordance with relevant guidelines and regulations along with the approval. In case of file failure, the information was completed by telephone or interview with the patient, during obtaining his informed consent and one of the conditions for entering the study was to be at least 30 years old.

The data of this study have collected from the National Diabetes Screening plan, which in case of incomplete information, the national plan implementers have collected the information by telephone or in-person from patients. Therefore, the present study has completed the data from the main screening plan due to its confidentiality (without stating the personal details of individuals such as name and surname). Due to the confidentiality and indirect relationship between the
researchers of this project and the samples, the ethics committee has considered the permission of use of the data.

- Consent for publication

I attest to the fact that all authors listed on the title page have read the manuscript, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to BMC Public Health.

- Availability of data and materials

If anyone wants to access the data in this study, they can contact the Corresponding author for this study: Mina Motamedi Rad, E-mail: mina.motamedi@outlook.com

- Competing interests

The authors declare no Competing interests

- Funding

This article is a part of M.S thesis of Biostatistics under the title of Evaluation of factors affecting to event time of neuropathy in patients with type 2 diabetes in the presence of surrogate endpoint. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

- Authors' contributions

Jamileh Abolghasemi: Supervision, Writing- Reviewing and Editing.
Mina Motamedi Rad: Software, Data curation, Writing- Original draft preparation, Investigation.
Fahimeh Soheilipour and Hamid Reza Baradaran: Writing- Reviewing and Editing.
Shahnaz Rimaz and Sadegh Kargarian Marvasti: Data curation

- Acknowledgements

We thank all the staff of the Isfahan Fereydunshahr Health Centers, who contributed to data collection.
References

1. Freeman R. Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy. Current diabetes reports. 2009;9(6):423-31.

2. Association AD. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes- 2020. Diabetes Care. 2020;43(Supplement 1):S135-S51.

3. Feldman EL, Stevens M, Thomas P, Brown M, Canal N, Greene D. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes care. 1994;17(11):1281-9.

4. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes care. 1998;21(9):1414-31.

5. Heidari Safa M. Peripheral diabetic neuropathy. Novin 2010;475:374-84.

6. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & therapeutics. 2008;120(1):1-34.

7. Tesfaye S, Stevens L, Stephenson J, Fuller J, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377-84.

8. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine. 1995;333(2):89-94.

9. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes care. 2017;40(1):136-54.

10. Lunetta M, Le Moli R, Grasso G, Sangiorgio L. A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy. Diabetes research and clinical practice. 1998;39(3):165-72.

11. Armstrong DG. The 10-g monofilament: the diagnostic divining rod for the diabetic foot? Diabetes care. 2000;23(7):887-91.

12. Buyse M, Molenberghs G, Paolletti X, Oba K, Alonso A, Van der Elst W, et al. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biometrical Journal. 2016;58(1):104-32.

13. Sun T, Liu Y, Cook RJ, Chen W, Ding Y. Copula-based score test for bivariate time-to-event data, with application to a genetic study of AMD progression. Lifetime data analysis. 2019;25(3):5381-97.

14. Hung H, Chiang CT. Estimation methods for time-dependent AUC models with survival data. Biometrics. 2010;38(1):8-26.

15. Nicholson G. Penetration of the hereditary motor and sensory neuropathy la mutation: Assessment by nerve conduction studies. Neurology. 1991;41(4):547-44.

16. Trivedi JR, Phillips L, Chhabra A, editors. Hereditary and acquired polyneuropathy conditions of the peripheral nerves: clinical considerations and MR neurography imaging. Seminars in musculoskeletal radiology; 2015: Thieme Medical Publishers.

17. Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, et al. VEGF gene polymorphism association with diabetic neuropathy. Molecular biology reports. 2010;37(7):3625-30.
Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. BMC neurology. 2005;5(1):24.

Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes care. 2011;34(10):2220-4.

Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989 Nov 1;38(11):1456-61.

Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Annals of Saudi medicine. 2007;27(1):25-31.

Ugoya SO, Ugoya TA, Puepet FH, Agaba EI, Oggunniyi AO. Risk determinants of diabetic peripheral neuropathy in Jos, North Central Nigeria. J of Chinese Clinical Medicine. 2008;3(5):285-91.

J. P. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete & metabolism. 1977; 3: 245-56.

Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy: results of the Seattle Prospective Diabetic Foot Study. Diabetes care. 1997;20(7):1162-7.

Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical diabetes. 2008;26(2):77-82.

Ardeshir Larijani MB BHM, Pajoohi M, Afshari M, Khani M, Shajarian M. Prevalence of limb amputation in patients with diabetic foot ulcers admitted to Shariati and Imam Khomeini hospitals in Tehran from 1979 to 1994. Iranian Journal of Diabetes and Lipids University of Tehran.2001(1):83-5.

Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Current diabetes reports. 2014;14(9):528.

Nathan DM, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes care. 2014;37(1):9-16.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet. 2010;376(9739):419-30.